CRBN-based PROTAC CW-10201 degrades KRAS G12D/G12V mutants, inducing tumor regression in xenograft models.
Background
KRAS mutations are pivotal drivers in over 50% of human cancers carrying mutated KRAS protein, particularly G12D and G12V variants, which are notoriously difficult to target directly. These mutations lock KRAS in an active, GTP-bound state, promoting uncontrolled cell proliferation and survival. Current therapeutic strategies often struggle with the lack of deep, druggable pockets on KRAS and the development of resistance. Induced protein degradation, via technologies like PROTACs, offers a novel approach by hijacking the cell's ubiquitin-proteasome system to selectively eliminate oncogenic proteins, bypassing traditional inhibition challenges. This strategy holds significant promise for intractable targets such as mutant KRAS.
Study Design
Researchers designed, synthesized, and evaluated novel PROTAC KRAS degraders utilizing a new cereblon (CRBN) ligand. This led to the identification of CW-10201. The compound's efficacy was assessed in vitro by measuring its ability to induce degradation of KRASG12D and KRASG12V mutants in various cancer cell lines. Cell growth inhibition was quantified via IC50 values. In vivo studies were conducted in mouse xenograft models, specifically using SW1990 KRASG12D and SW620 KRASG12V mutated tumor models, to evaluate pharmacokinetic (PK), pharmacodynamic (PD), and anti-tumor properties of CW-10201 at well-tolerated doses.
Results
CW-10201 demonstrated potent efficacy, inducing degradation of KRASG12D and KRASG12V mutants at low nanomolar concentrations in cellular assays. It exhibited excellent pharmacokinetic and pharmacodynamic properties in mice, indicating favorable drug-like characteristics for in vivo application. In preclinical animal models, CW-10201 was capable of attaining tumor regression in the SW1990 KRASG12D mutated xenograft model. Furthermore, it effectively inhibited tumor growth in the SW620 KRASG12V xenograft tumor model in mice, with all observed effects occurring at well-tolerated doses. These findings highlight CW-10201's potential as a highly effective degrader for these specific KRAS mutations. > It achieved IC50 values of 2-4 nM for inhibiting cell growth in cancer cell lines harboring either KRASG12D or KRASG12V mutations, showcasing its potent anti-proliferative effects.
Why It Matters
The discovery of CW-10201 represents a significant advance in targeting KRAS G12D and G12V mutations, which are notoriously challenging and drive a large proportion of human cancers. This PROTAC approach offers a distinct advantage over traditional inhibitors by completely eliminating the oncogenic protein, potentially overcoming resistance mechanisms and achieving deeper, more durable responses. For future clinical translation, this work provides a strong foundation for developing a novel class of therapeutics for patients with KRAS-mutated cancers. While still in preclinical stages, the robust in vitro and in vivo efficacy suggests CW-10201 or its optimized derivatives could eventually offer a new, highly effective treatment option, potentially impacting patient protocols by providing a targeted degradation strategy where current options are limited.
